Johnson & Johnson Says Imaavy Shows Sustained Disease Control in Myasthenia Gravis
-- Johnson & Johnson (JNJ) said Wednesday that new phase 3 data demonstrates that Imaavy provides sustained disease control over more than two years in patients with generalized myasthenia gravis.
The phase 3 study and its open-label extension showed sustained improvements in symptoms and quality of life over 120 weeks, along with durable reductions in disease-driving antibodies, with many patients achieving and maintaining minimal symptom expression, the company said.
Johnson & Johnson also said its EPIC study, the first head-to-head study of Imaavy versus another FcRn blocker in generalized myasthenia gravis, is now enrolling participants